Your browser doesn't support javascript.
loading
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo, Courtney D; Rausch, Caitlin R; Benton, Christopher; Kadia, Tapan; Jain, Nitin; Pemmaraju, Naveen; Daver, Naval; Covert, Wendy; Marx, Kayleigh R; Mace, Morgan; Jabbour, Elias; Cortes, Jorge; Garcia-Manero, Guillermo; Ravandi, Farhad; Bhalla, Kapil N; Kantarjian, Hagop; Konopleva, Marina.
Afiliação
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rausch CR; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Benton C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Covert W; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Marx KR; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mace M; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cortes J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bhalla KN; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Am J Hematol ; 93(3): 401-407, 2018 03.
Article em En | MEDLINE | ID: mdl-29218851
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia de Salvação / Proteínas Proto-Oncogênicas c-bcl-2 / Terapia de Alvo Molecular / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia de Salvação / Proteínas Proto-Oncogênicas c-bcl-2 / Terapia de Alvo Molecular / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article